Clinical Trial Update: Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This document outlines a Phase 2 trial evaluating pasireotide LAR in combination with topotecan for relapsed or refractory small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Pasireotide LAR (pasireotide)
• Topotecan (topotecan)

Snippet

Sponsor: South Florida Veterans Affairs Foundation for Research and Education | Conditions: Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN